zentalis_logo_large.jpg
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
November 09, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
Six sponsored studies with potentially first-in-class Wee1 inhibitor, ZN-c3, ongoing and continuing dose optimization work, as drug continues to show improved tolerability in initial safety data from...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference
November 08, 2022 07:01 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022 17:38 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer
October 24, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy
October 17, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022 17:32 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer
September 27, 2022 16:01 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer
September 19, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
September 12, 2022 07:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing...
zentalis_logo_large.jpg
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2022 17:00 ET | ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...